These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 27317414)

  • 1. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
    Glund S; Stangier J; van Ryn J; Schmohl M; Moschetti V; Haazen W; De Smet M; Gansser D; Norris S; Lang B; Reilly P; Kreuzer J
    Clin Pharmacokinet; 2017 Jan; 56(1):41-54. PubMed ID: 27317414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study.
    Wang Z; Zhao X; He P; Chen S; Jiang J; Harada A; Brooks S; Cui Y
    Adv Ther; 2020 Sep; 37(9):3916-3928. PubMed ID: 32691242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran.
    Glund S; Coble K; Gansser D; Stangier J; Hoermann K; Pollack CV; Reilly P
    J Thromb Haemost; 2019 Aug; 17(8):1319-1328. PubMed ID: 31050868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
    Yasaka M; Ikushima I; Harada A; Imazu S; Taniguchi A; Norris S; Gansser D; Stangier J; Schmohl M; Reilly PA
    Res Pract Thromb Haemost; 2017 Oct; 1(2):202-215. PubMed ID: 30046691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.
    Glund S; Moschetti V; Norris S; Stangier J; Schmohl M; van Ryn J; Lang B; Ramael S; Reilly P
    Thromb Haemost; 2015 May; 113(5):943-51. PubMed ID: 25789661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
    Norris S; Ramael S; Ikushima I; Haazen W; Harada A; Moschetti V; Imazu S; Reilly PA; Lang B; Stangier J; Glund S
    Br J Clin Pharmacol; 2017 Aug; 83(8):1815-1825. PubMed ID: 28230262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Emerg Med; 2016 Nov; 34(11S):26-32. PubMed ID: 27707528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
    Reilly PA; van Ryn J; Grottke O; Glund S; Stangier J
    Am J Med; 2016 Nov; 129(11S):S64-S72. PubMed ID: 27569674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
    Kamel KS; Chin PK; Doogue MP; Barclay ML
    Clin Pharmacokinet; 2017 Feb; 56(2):207-208. PubMed ID: 28035591
    [No Abstract]   [Full Text] [Related]  

  • 13. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
    Brennan Y; Favaloro EJ; Pasalic L; Keenan H; Curnow J
    Intern Med J; 2019 Jan; 49(1):59-65. PubMed ID: 29869387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
    Van der Wall SJ; Lopes RD; Aisenberg J; Reilly P; van Ryn J; Glund S; Elsaesser A; Klok FA; Pollack CV; Huisman MV
    Circulation; 2019 Feb; 139(6):748-756. PubMed ID: 30586692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination.
    Glund S; Gan G; Moschetti V; Reilly P; Honickel M; Grottke O; Van Ryn J
    Clin Appl Thromb Hemost; 2018 Jul; 24(5):724-733. PubMed ID: 29534609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P
    Drug Des Devel Ther; 2016; 10():1683-9. PubMed ID: 27274201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab for dabigatran overdose.
    Peetermans M; Pollack C; Reilly P; Liesenborghs L; Jacquemin M; Levy JH; Weitz JI; Verhamme P
    Clin Toxicol (Phila); 2016 Sep; 54(8):644-6. PubMed ID: 27224445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.